NeuroMetrix Launches Second Generation SENSUS Device

  NeuroMetrix Launches Second Generation SENSUS Device  Business Wire  WALTHAM, Mass. -- March 18, 2014  NeuroMetrix, Inc. (the “Company”) (Nasdaq:NURO), an innovative health care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances, today reported first shipments of the second generation of its wearable therapeutic technology, the SENSUS^™  Pain Management System.  SENSUS technology utilizes comfortable, non-invasive electrical nerve stimulation of sensory nerves to induce a safe and effective elevation in the level of naturally occurring neuromodulatory chemicals, called enkephalins, which block the transmission of pain signals throughout the nervous system. As a result, many patients experience fast-acting, non-narcotic relief from chronic pain when using SENSUS.  SENSUS is a transcutaneous electrical nerve stimulator with broad regulatory indications for management of chronic pain and is the only such device cleared by the FDA specifically for use during sleep. The device is lightweight and can be worn during the day while remaining active, and at night while sleeping. It incorporates a tri-axial MEMS accelerometer that monitors patient body position and movement enabling automatic regulation of therapeutic parameters.  The device is designed for people with diabetes that suffer from chronic pain. The most common cause of such pain is painful diabetic neuropathy (PDN), which affects up to 5 million people in the U.S. alone. Additional forms of chronic pain that may benefit from transcutaneous electrical nerve stimulation include fibromyalgia, post herpetic neuropathy (shingles), and conditions with both chronic pain and disturbed sleep such as restless leg syndrome.  The second-generation SENSUS builds on the successful launch of the technology in early 2013. Over 2000 first generation devices have shipped since launch. The second-generation device is about 20% thinner and has several key hardware improvements. The thinner design makes the device more discreet when worn under clothing and more comfortable during sleep.  “The launch of our second generation SENSUS device demonstrates our scientific capabilities in wearable medical technology and commitment to continual innovation. Feedback from patients and physicians on the over 2000 first generation devices in use has been positive and provided us with a road-map for further improvements, many of which are incorporated into the second generation device,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive Officer of NeuroMetrix. “In addition to the use of SENSUS in managing chronic pain, the novel integration of electrical stimulation and activity tracking through the embedded accelerometer offers exciting opportunities to develop wearable therapeutic devices for a variety of medical conditions.”  About NeuroMetrix  NeuroMetrix is an innovative health-care company that develops wearable medical technology and point-of-care diagnostics that help patients and physicians better manage chronic pain, nerve disorders, and associated sleep disturbances. The Company has a major focus on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS^™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy and other forms of chronic pain such as fibromyalgia, post herpetic neuropathy (shingles), and conditions with both chronic pain and disturbed sleep such as restless leg syndrome. The company also markets the DPNCheck^® device, which is a rapid, accurate, and quantitative point-of-care test for peripheral neuropathies such as diabetic neuropathy. This product is used to detect neuropathies at an early stage and to guide treatment. For more information, please visit http://www.NeuroMetrix.com.  Contact:  NeuroMetrix, Inc. Thomas T. Higgins, 781-314-2761 SVP and Chief Financial Officer neurometrix.ir@neurometrix.com